Atossa Therapeutics’ (ATOS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a report published on Monday, Benzinga reports. They currently have a $6.00 price target on the stock.

ATOS has been the topic of several other research reports. Ascendiant Capital Markets lifted their price target on Atossa Therapeutics from $6.00 to $6.25 and gave the stock a buy rating in a research report on Thursday, June 6th. StockNews.com upgraded Atossa Therapeutics from a sell rating to a hold rating in a research note on Tuesday, May 14th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Atossa Therapeutics in a research note on Thursday, June 20th.

Atossa Therapeutics Stock Down 4.6 %

ATOS opened at $1.24 on Monday. The firm has a market cap of $155.94 million, a price-to-earnings ratio of -5.17 and a beta of 1.21. Atossa Therapeutics has a 52 week low of $0.62 and a 52 week high of $2.31. The business’s 50 day moving average is $1.24 and its two-hundred day moving average is $1.33.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. Equities analysts expect that Atossa Therapeutics will post -0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of Atossa Therapeutics in the second quarter valued at approximately $29,000. Renaissance Technologies LLC boosted its position in Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after purchasing an additional 164,540 shares in the last quarter. Rhumbline Advisers purchased a new stake in Atossa Therapeutics during the second quarter worth $161,000. Bank of New York Mellon Corp boosted its position in Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after purchasing an additional 399,041 shares in the last quarter. Finally, Cetera Advisors LLC purchased a new stake in Atossa Therapeutics during the first quarter worth $72,000. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.